& irkin, B
However, just a limited number of agents have received approval or are undergoing clinical trials for conditions such as iron overload-related diseases
Tesamorelin is selected for specific clinical profiles where the more potent intervention is warranted
Researchers are exploring whether targeting multiple pathways can lead to greater average weight reduction in controlled trial settings
Clinical Trial Results STEP Trials (Semaglutide) The STEP program studied semaglutide 2.4 mg weekly in overweight/obese adults: STEP 1 : 16.9% average weight loss over 68 weeks vs 2.4% placebo STEP 2 (T2D patients): 9.6% weight loss STEP 3 (with behavioral therapy): 16.0% weight loss STEP 5 (2-year data): 15.2% sustained weight loss SURMOUNT Trials (Tirzepatide) The SURMOUNT program studied tirzepatide at 5mg, 10mg, and 15mg weekly: SURMOUNT-1 : 20.9% average weight loss at 15mg over 72 weeks vs 3.1% placebo SURMOUNT-2 (T2D patients): 14.7% at 15mg SURMOUNT-3 (with lifestyle intervention): 26.6% at highest dose SURMOUNT-4 (maintenance): continued weight loss vs weight regain on placebo Head-to-Head No large head-to-head trial has directly compared them at optimal doses for weight loss

GLP-1 receptor agonists are medications (such as semaglutide, tirzepatide, and liraglutide) that mimic a natural gut hormone, helping lower blood sugar, reduce appetite, promote weight loss, and decrease inflammation. Can GLP-1 medications help with both diabetes and weight loss